Colon  ||| S:0 E:6 ||| NN
epithelial  ||| S:6 E:17 ||| NN
proliferation  ||| S:17 E:31 ||| NN
and  ||| S:31 E:35 ||| CC
carcinogenesis  ||| S:35 E:50 ||| NN
in  ||| S:50 E:53 ||| IN
diet-induced  ||| S:53 E:66 ||| JJ
obesity  ||| S:66 E:74 ||| JJ
Colorectal  ||| S:74 E:85 ||| JJ
cancer  ||| S:85 E:92 ||| NN
is  ||| S:92 E:95 ||| VBZ
the  ||| S:95 E:99 ||| DT
third  ||| S:99 E:105 ||| JJ
leading  ||| S:105 E:113 ||| JJ
cause  ||| S:113 E:119 ||| NN
of  ||| S:119 E:122 ||| IN
cancer  ||| S:122 E:129 ||| NN
death  ||| S:129 E:135 ||| NN
in  ||| S:135 E:138 ||| IN
Japan  ||| S:138 E:144 ||| NNP
and  ||| S:144 E:148 ||| CC
the  ||| S:148 E:152 ||| DT
United  ||| S:152 E:159 ||| NNP
States  ||| S:159 E:166 ||| NNPS
and  ||| S:166 E:170 ||| CC
is  ||| S:170 E:173 ||| VBZ
strongly  ||| S:173 E:182 ||| RB
associated  ||| S:182 E:193 ||| VBN
with  ||| S:193 E:198 ||| IN
obesity ||| S:198 E:205 ||| NN
,  ||| S:205 E:207 ||| ,
especially  ||| S:207 E:218 ||| RB
visceral  ||| S:218 E:227 ||| JJ
obesity ||| S:227 E:234 ||| NN
.  ||| S:234 E:236 ||| .
Several  ||| S:236 E:244 ||| JJ
metabolic  ||| S:244 E:254 ||| JJ
mediators ||| S:254 E:263 ||| NNS
,  ||| S:263 E:265 ||| ,
such  ||| S:265 E:270 ||| JJ
as  ||| S:270 E:273 ||| IN
adiponectin ||| S:273 E:284 ||| NN
,  ||| S:284 E:286 ||| ,
have  ||| S:286 E:291 ||| VBP
been  ||| S:291 E:296 ||| VBN
suspected  ||| S:296 E:306 ||| VBN
to  ||| S:306 E:309 ||| TO
play  ||| S:309 E:314 ||| VB
a  ||| S:314 E:316 ||| DT
role  ||| S:316 E:321 ||| NN
in  ||| S:321 E:324 ||| IN
obesity-related  ||| S:324 E:340 ||| JJ
carcinogenesis ||| S:340 E:354 ||| NN
.  ||| S:354 E:356 ||| .
In  ||| S:356 E:359 ||| IN
a  ||| S:359 E:361 ||| DT
previous  ||| S:361 E:370 ||| JJ
human  ||| S:370 E:376 ||| JJ
study ||| S:376 E:381 ||| NN
,  ||| S:381 E:383 ||| ,
the  ||| S:383 E:387 ||| DT
existence  ||| S:387 E:397 ||| NN
of  ||| S:397 E:400 ||| IN
a  ||| S:400 E:402 ||| DT
significant  ||| S:402 E:414 ||| JJ
correlation  ||| S:414 E:426 ||| NN
between  ||| S:426 E:434 ||| IN
the  ||| S:434 E:438 ||| DT
number  ||| S:438 E:445 ||| NN
of  ||| S:445 E:448 ||| IN
human  ||| S:448 E:454 ||| JJ
dysplastic  ||| S:454 E:465 ||| FW
aberrant  ||| S:465 E:474 ||| FW
crypt  ||| S:474 E:480 ||| FW
foci  ||| S:480 E:485 ||| FW
( ||| S:485 E:486 ||| -LRB-
ACF ||| S:486 E:489 ||| NNP
)  ||| S:489 E:491 ||| -RRB-
and  ||| S:491 E:495 ||| CC
the  ||| S:495 E:499 ||| DT
visceral  ||| S:499 E:508 ||| JJ
fat  ||| S:508 E:512 ||| JJ
area  ||| S:512 E:517 ||| NN
was  ||| S:517 E:521 ||| VBD
demonstrated ||| S:521 E:533 ||| VBN
,  ||| S:533 E:535 ||| ,
and  ||| S:535 E:539 ||| CC
also  ||| S:539 E:544 ||| RB
that  ||| S:544 E:549 ||| IN
of  ||| S:549 E:552 ||| IN
a  ||| S:552 E:554 ||| DT
significant  ||| S:554 E:566 ||| JJ
inverse  ||| S:566 E:574 ||| JJ
correlation  ||| S:574 E:586 ||| NN
between  ||| S:586 E:594 ||| IN
the  ||| S:594 E:598 ||| DT
number  ||| S:598 E:605 ||| NN
of  ||| S:605 E:608 ||| IN
dysplastic  ||| S:608 E:619 ||| JJ
ACF  ||| S:619 E:623 ||| NNP
and  ||| S:623 E:627 ||| CC
the  ||| S:627 E:631 ||| DT
plasma  ||| S:631 E:638 ||| JJ
adiponectin  ||| S:638 E:650 ||| JJ
level ||| S:650 E:655 ||| NN
.  ||| S:655 E:657 ||| .
Other  ||| S:657 E:663 ||| JJ
studies  ||| S:663 E:671 ||| NNS
have  ||| S:671 E:676 ||| VBP
investigated  ||| S:676 E:689 ||| VBN
the  ||| S:689 E:693 ||| DT
effect  ||| S:693 E:700 ||| NN
of  ||| S:700 E:703 ||| IN
adiponectin  ||| S:703 E:715 ||| NN
under  ||| S:715 E:721 ||| IN
the  ||| S:721 E:725 ||| DT
normal  ||| S:725 E:732 ||| JJ
and  ||| S:732 E:736 ||| CC
high-fat  ||| S:736 E:745 ||| JJ
diet  ||| S:745 E:750 ||| NN
conditions  ||| S:750 E:761 ||| NNS
in  ||| S:761 E:764 ||| IN
a  ||| S:764 E:766 ||| DT
mouse  ||| S:766 E:772 ||| NN
model  ||| S:772 E:778 ||| NN
of  ||| S:778 E:781 ||| IN
azoxymethane-induced  ||| S:781 E:802 ||| JJ
colon  ||| S:802 E:808 ||| NN
cancer ||| S:808 E:814 ||| NN
.  ||| S:814 E:816 ||| .
Enhanced  ||| S:816 E:825 ||| JJ
formation  ||| S:825 E:835 ||| NN
of  ||| S:835 E:838 ||| IN
both  ||| S:838 E:843 ||| DT
ACF  ||| S:843 E:847 ||| NNP
and  ||| S:847 E:851 ||| CC
tumors  ||| S:851 E:858 ||| NNS
was  ||| S:858 E:862 ||| VBD
observed  ||| S:862 E:871 ||| VBN
in  ||| S:871 E:874 ||| IN
the  ||| S:874 E:878 ||| DT
adiponectin-deficient  ||| S:878 E:900 ||| JJ
mice ||| S:900 E:904 ||| NNS
,  ||| S:904 E:906 ||| ,
as  ||| S:906 E:909 ||| RB
compared  ||| S:909 E:918 ||| VBN
with  ||| S:918 E:923 ||| IN
that  ||| S:923 E:928 ||| DT
in  ||| S:928 E:931 ||| IN
the  ||| S:931 E:935 ||| DT
wild-type ||| S:935 E:944 ||| JJ
,  ||| S:944 E:946 ||| ,
under  ||| S:946 E:952 ||| IN
the  ||| S:952 E:956 ||| DT
high-fat  ||| S:956 E:965 ||| JJ
diet  ||| S:965 E:970 ||| NN
condition  ||| S:970 E:980 ||| NN
but  ||| S:980 E:984 ||| CC
not  ||| S:984 E:988 ||| RB
under  ||| S:988 E:994 ||| IN
the  ||| S:994 E:998 ||| DT
normal  ||| S:998 E:1005 ||| JJ
diet  ||| S:1005 E:1010 ||| NN
condition ||| S:1010 E:1019 ||| NN
.  ||| S:1019 E:1021 ||| .
Furthermore ||| S:1021 E:1032 ||| RB
,  ||| S:1032 E:1034 ||| ,
that  ||| S:1034 E:1039 ||| IN
the  ||| S:1039 E:1043 ||| DT
5 ||| S:1043 E:1044 ||| CD
' ||| S:1044 E:1045 ||| POS
-AMP-activated  ||| S:1045 E:1060 ||| JJ
kinase ||| S:1060 E:1066 ||| NNS
/ ||| S:1066 E:1067 ||| VBP
mammalian  ||| S:1067 E:1077 ||| JJ
target  ||| S:1077 E:1084 ||| NN
of  ||| S:1084 E:1087 ||| IN
rapamycin  ||| S:1087 E:1097 ||| JJ
pathway  ||| S:1097 E:1105 ||| NN
is  ||| S:1105 E:1108 ||| VBZ
involved  ||| S:1108 E:1117 ||| VBN
in  ||| S:1117 E:1120 ||| IN
the  ||| S:1120 E:1124 ||| DT
promotion  ||| S:1124 E:1134 ||| NN
of  ||| S:1134 E:1137 ||| IN
colorectal  ||| S:1137 E:1148 ||| JJ
carcinogenesis  ||| S:1148 E:1163 ||| NN
in  ||| S:1163 E:1166 ||| IN
adiponectin-deficient  ||| S:1166 E:1188 ||| JJ
mice  ||| S:1188 E:1193 ||| NNS
under  ||| S:1193 E:1199 ||| IN
the  ||| S:1199 E:1203 ||| DT
high-fat  ||| S:1203 E:1212 ||| JJ
diet  ||| S:1212 E:1217 ||| NN
condition  ||| S:1217 E:1227 ||| NN
was  ||| S:1227 E:1231 ||| VBD
shown ||| S:1231 E:1236 ||| VBN
.  ||| S:1236 E:1238 ||| .
Therefore ||| S:1238 E:1247 ||| RB
,  ||| S:1247 E:1249 ||| ,
that  ||| S:1249 E:1254 ||| IN
the  ||| S:1254 E:1258 ||| DT
5 ||| S:1258 E:1259 ||| CD
' ||| S:1259 E:1260 ||| POS
-AMP-activated  ||| S:1260 E:1275 ||| JJ
kinase ||| S:1275 E:1281 ||| NNS
/ ||| S:1281 E:1282 ||| VBP
mammalian  ||| S:1282 E:1292 ||| JJ
target  ||| S:1292 E:1299 ||| NN
of  ||| S:1299 E:1302 ||| IN
rapamycin  ||| S:1302 E:1312 ||| JJ
signaling  ||| S:1312 E:1322 ||| JJ
pathway  ||| S:1322 E:1330 ||| NN
may  ||| S:1330 E:1334 ||| MD
play  ||| S:1334 E:1339 ||| VB
an  ||| S:1339 E:1342 ||| DT
important  ||| S:1342 E:1352 ||| JJ
role  ||| S:1352 E:1357 ||| NN
in  ||| S:1357 E:1360 ||| IN
colorectal  ||| S:1360 E:1371 ||| JJ
carcinogenesis  ||| S:1371 E:1386 ||| NN
was  ||| S:1386 E:1390 ||| VBD
speculated ||| S:1390 E:1400 ||| VBN
.  ||| S:1400 E:1402 ||| .
Metformin ||| S:1402 E:1411 ||| NNP
,  ||| S:1411 E:1413 ||| ,
a  ||| S:1413 E:1415 ||| DT
biguanide  ||| S:1415 E:1425 ||| JJ
derivative  ||| S:1425 E:1436 ||| JJ
widely  ||| S:1436 E:1443 ||| RB
used  ||| S:1443 E:1448 ||| VBN
in  ||| S:1448 E:1451 ||| IN
the  ||| S:1451 E:1455 ||| DT
treatment  ||| S:1455 E:1465 ||| NN
of  ||| S:1465 E:1468 ||| IN
diabetes  ||| S:1468 E:1477 ||| JJ
mellitus ||| S:1477 E:1485 ||| NN
,  ||| S:1485 E:1487 ||| ,
has  ||| S:1487 E:1491 ||| VBZ
been  ||| S:1491 E:1496 ||| VBN
shown  ||| S:1496 E:1502 ||| VBN
to  ||| S:1502 E:1505 ||| TO
exert  ||| S:1505 E:1511 ||| VB
a  ||| S:1511 E:1513 ||| DT
suppressive  ||| S:1513 E:1525 ||| JJ
effect  ||| S:1525 E:1532 ||| NN
on  ||| S:1532 E:1535 ||| IN
ACF  ||| S:1535 E:1539 ||| NNP
formation  ||| S:1539 E:1549 ||| NN
in  ||| S:1549 E:1552 ||| IN
both  ||| S:1552 E:1557 ||| DT
mouse  ||| S:1557 E:1563 ||| NN
models  ||| S:1563 E:1570 ||| NNS
and  ||| S:1570 E:1574 ||| CC
humans ||| S:1574 E:1580 ||| NNS
.  ||| S:1580 E:1582 ||| .
Therefore ||| S:1582 E:1591 ||| RB
,  ||| S:1591 E:1593 ||| ,
metformin  ||| S:1593 E:1603 ||| NNS
might  ||| S:1603 E:1609 ||| MD
be  ||| S:1609 E:1612 ||| VB
a  ||| S:1612 E:1614 ||| DT
promising  ||| S:1614 E:1624 ||| JJ
candidate  ||| S:1624 E:1634 ||| NN
as  ||| S:1634 E:1637 ||| IN
a  ||| S:1637 E:1639 ||| DT
safe  ||| S:1639 E:1644 ||| JJ
drug  ||| S:1644 E:1649 ||| NN
for  ||| S:1649 E:1653 ||| IN
chemoprevention  ||| S:1653 E:1669 ||| NN
of  ||| S:1669 E:1672 ||| IN
colorectal  ||| S:1672 E:1683 ||| JJ
carcinogenesis ||| S:1683 E:1697 ||| NN
.  ||| S:1697 E:1699 ||| .
Further  ||| S:1699 E:1707 ||| JJ
studies  ||| S:1707 E:1715 ||| NNS
with  ||| S:1715 E:1720 ||| IN
high  ||| S:1720 E:1725 ||| JJ
evidence  ||| S:1725 E:1734 ||| NN
levels ||| S:1734 E:1740 ||| NNS
,  ||| S:1740 E:1742 ||| ,
such  ||| S:1742 E:1747 ||| JJ
as  ||| S:1747 E:1750 ||| IN
randomized ||| S:1750 E:1760 ||| NN
,  ||| S:1760 E:1762 ||| ,
controlled  ||| S:1762 E:1773 ||| VBN
studies ||| S:1773 E:1780 ||| NNS
,  ||| S:1780 E:1782 ||| ,
are  ||| S:1782 E:1786 ||| VBP
needed  ||| S:1786 E:1793 ||| VBN
to  ||| S:1793 E:1796 ||| TO
clarify  ||| S:1796 E:1804 ||| VB
these  ||| S:1804 E:1810 ||| DT
relationships ||| S:1810 E:1823 ||| NNS
.  ||| S:1823 E:1825 ||| .
